MedTrace Logo

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

NCT03316599 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-08-03

No results posted yet for this study

Summary

To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.

Conditions

Interventions

DRUG

Gemcitabine

Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

DRUG

Nab-paclitaxel

Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells

DRUG

Ficlatuzumab

It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.

Sponsors & Collaborators

Principal Investigators

  • Kimberly Perez, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-17
Primary Completion
2020-10-10
Completion
2021-07-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316599 on ClinicalTrials.gov